Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell receptor, chemokine, and integrin-mediated signaling. In early-phase studies, ibrutinib demonstrated high response rates and prolonged progression-free survival (PFS) in chronic lymphocytic leukemia (CLL)...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood
Auteurs principaux: Byrd, John C., Furman, Richard R., Coutre, Steven E., Burger, Jan A., Blum, Kristie A., Coleman, Morton, Wierda, William G., Jones, Jeffrey A., Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Shaw, Yun, Bilotti, Elizabeth, Zhou, Cathy, James, Danelle F., O'Brien, Susan
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2015
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4400288/
https://ncbi.nlm.nih.gov/pubmed/25700432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-10-606038
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires